Citations (7)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Basilio Colligris, Almudena Crooke, Fernando Huete-Toral & Jesus Pintor. (2014) An update on dry eye disease molecular treatment: advances in drug pipelines. Expert Opinion on Pharmacotherapy 15:10, pages 1371-1390.
Read now
Read now
Articles from other publishers (6)
Noriaki NishidaYuko ShikamuraAkiharu Isowaki. (2022) Development of Azimycin<sup>Ⓡ</sup> ophthalmic solution 1％ based on ophthalmic DDS technology “DuraSite<sup>Ⓡ</sup>”眼科用DDS技術「DuraSite<sup>Ⓡ</sup>」を応用したアジマイシン<sup>Ⓡ</sup>点眼液1％の開発. Drug Delivery System 37:4, pages 349-353.
Crossref
Crossref
Hussein M. Eid, Ibrahim A. Naguib, Reem I. Alsantali, Izzeddin Alsalahat & Amira M. Hegazy. (2021) Novel Chitosan-Coated Niosomal Formulation for Improved Management of Bacterial Conjunctivitis: A Highly Permeable and Efficient Ocular Nanocarrier for Azithromycin. Journal of Pharmaceutical Sciences 110:8, pages 3027-3036.
Crossref
Crossref
Yesim AltayGulizar DemirokOzgur BaltaHulya Bolu. (2017)
RETRACTED:
Azithromycin 1.5% Ophthalmic Solution for Blepharitis Treatment: Comparison of 14- Versus 30-Day Treatment
. Journal of Ocular Pharmacology and Therapeutics 33:10, pages e781-e787.
Crossref
Crossref
Jamil R. Azzi, Mohamed H. Sayegh & Samir G. Mallat. (2013) Calcineurin Inhibitors: 40 Years Later, Can’t Live Without …. The Journal of Immunology 191:12, pages 5785-5791.
Crossref
Crossref
Gary N. Foulks. 2013. Ocular Surface Disease: Cornea, Conjunctiva and Tear Film. Ocular Surface Disease: Cornea, Conjunctiva and Tear Film
67
76
.
Dominick L. OpitzJennifer S. Harthan. (2012) Review of Azithromycin Ophthalmic 1% Solution (AzaSite®) for the Treatment of Ocular Infections. Ophthalmology and Eye Diseases 4, pages OED.S7791.
Crossref
Crossref